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Abstract
Introduction: Unwanted pregnancy can endanger reproductive health, and its 
complications could adversely affect quality of life in females, families, and the 
community. A large number of unwanted pregnancies are terminated with abortion or 
stillbirth. Sex is an important aspect of quality of life. According to reproductive rights, 
females have the right to experience a safe and enjoyable sexual relationship. This study 
aimed at comparing sexual function scores between females taking combined oral 
contraceptives and Cyclofem at health centers affiliated to Shahid Beheshti University 
of Medical Sciences of Tehran, Iran, During Year 2013.
Methods: This descriptive-comparative study was carried -out on 240 females (each 
group 120) in Tehran, Iran, by multistage sampling. Data collection tools had 3 parts; 
General Health Questionnaire (GHQ), demographic variables, and Female Sexual 
Function Index (FSFI) that were completed by interviews. Descriptive statistics, 
independent t, Mann-Whitney test, chi-square, and SPPS16 were used for analysis of 
data. P-values less than 0.05 were considered statistically significant.
Results: The difference in sexual function between combined oral contraceptives and 
cyclofem was insignificant. Scores of desire and arousal dimensions were better in 
combined oral contraceptive consumers than cyclofem users.
Conclusions: It is important for females to choose hormonal contraception methods, 
which are the most effective, yet, cause the least sexual dysfunction.
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Annually, 46 million out of 87 million unwanted pregnan-
cies (more than 50%) do not result in live birth around the 
world. In 2008, 38 million abortions took place worldwide. 
According to the World Health Organization (WHO), one 
in every 10 pregnancies lead to unsafe abortion, and one in 
every 8 unsafe abortion leads to mother’s death. This inci-
dent occurs 6 times more in developing countries [1]. Ac-
cording to studies from Iran, one-third of pregnancies is un-
intended [2]. The risk of unintended pregnancies is less in 
females, who use hormonal methods of contraception [3]. 
Having high effectiveness, contraceptive methods are con-
sidered desirable because they are easy to use and do not 
interfere with intercourse [4]. In summary, access to highly 
effective reversible contraception offers a way to potentially 
decrease the incidence of unintended and mistimed preg-
nancies. The principle aim of family planning is to prevent 
unwanted pregnancies. Cyclofem is a type of combination 
injectable hormonal contraceptive. Cyclofem contains 0.5 
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ml of active ingredients, comprised of 25 mg of medroxy-
progesterone acetate and 5 mg of estradiol cypionate, and is 
injected on a monthly basis [5]. The efficacy of this method 
is 99.8% in the first year [6]. In 70 000 females per year, only 
6 cases of failure were reported. This rate of efficacy is sim-
ilar to that of sterilization in females. After discontinuation 
of the use of this product, return to fertility occurs much 
faster than progestin injection [7]. Only cyclofem has been 
introduced in Iran’s family planning program. Estradiol in 
cyclofem is intermediate acting, and maintains the high-
est plasma level for approximately 15 days, and is reduced 
3 weeks after administration, which presents as uterine 
bleeding. Cyclofem is an effective contraceptive method, 
with 0 to 0.2 cases of pregnancy in 100 females per year 
[8]. Combined Oral Contraceptives (COC) are safe and 
effective options for preventing pregnancy. Combined Oral 
Contraceptives are considered the most commonly used 
and popular contraceptive. Proper use of COC provides 
almost absolute protection against pregnancy [9]. Sex hor-
mones, such as estrogen and progesterone, could impose 
different effects on female’s sexual behaviors and functions 
through vaginal tissue and the central nervous system [10]. 
Studies have indicated that hormones used in contraceptive 
methods have effects on sexual function of females in repro-
ductive ages [11]. Females using hormonal contraceptive 
methods have experienced positive, negative or no effects 
on their libido [6]. Prevalence of sexual dysfunction was 
48.3% in Turkey, 22% in Chile and 49% in Brazil [12-14]. 
In Iran, sexual dysfunctions have a wide range from 8.5% 
[15] to 19.2% [16] and 31.5% [17]. Ramezani Tehrani et 
al. (2014) reported the prevalence of sexual dysfunction as 
27.3%, while frequency of desire, arousal, lubrication, and 
orgasmic disorders, were 18.6%, 39.9%, 18.9%, and 27.3%, 
respectively. They reported the 56.1% of females had dys-
pareunia and 15.2% were dissatisfied with their sexual life 
[18]. This problem is so important that it accounts for 88% 
of divorces [19].
One of the major side effects of hormonal contraception 
methods is their effect on sexuality and libido, which are 
one of the main reasons for discontinuation in females, 
who used hormonal contraception [20]. A  satisfaction 
with contraceptives depends upon lifestyle, side effects, 
and concern about the likelihood of pregnancy. Satisfactory 
sexual relationship increases satisfaction with life [4]. The 
current study aimed at determining whether cyclofem and 
COC effect sexual function and its aspects. There are effec-
tive methods for regulating fertility, yet, none is without 
complications [21]. In choosing contraceptive methods, 
females are faced with many challenges, including benefits 
and side-effects [22]. Lack of early and adequate training 
about sexual matters is a major concern for females of any 
age. The current study aimed at comparing the scores of 
sexual function of females using cyclofem with those us-
ing COC, attending the health centers affiliated to Shahid 
Beheshti University of Medical Sciences in Tehran, Iran, 
during year 2013.
METHODS
This descriptive comparative study was conducted from 
May to November 2013 with multistage sampling, includ-
ing 240 Iranian females, who lived in Tehran and referred 
to health care centers. The area of health care centers affil-
iated to Shahid Beheshti University of Medical Sciences in 
Tehran was divided to 4 zones, namely North, South, West, 
and East, and then 2 centers were randomly selected from 
each region. The Ethics Committee of Shahid Beheshti 
University of Medical Sciences, Tehran (Iran) approved 
this study. During sampling, participation in this study was 
voluntarily, and subjects could decline to continue at any 
stage of the study. The researcher introduced herself and 
explained the objectives of the study to the participants. 
Participants were assured of the confidentiality of their in-
formation. They were recruited according to the inclusion 
criteria. Study inclusion criteria were Iranian nationality, 
minimum of 3 months of use of contraceptive methods, no 
lactation, no addiction, psychological disorders or use of 
antidepressants in the any of the spouses, lack of adverse 
life event in the females over the 6 months prior to the 
study.
In this study, 264 females were registered. Because of the 
impact of depression and anxiety on sexual function, the 
28-item Persian version General Health Questionnaire 
(GHQ-28) was first completed for assessment mental 
health. The GHQ has been used in previous studies [23, 
24], and is scored on a Likert scale (not at all = 0, about 
normal = 1, more than normal = 2, and much more than 
normal = 3). It had 4 subscales, including somatic symp-
toms (7 questions), anxiety and sleep disorder (7 ques-
tions), social function (7 questions), and depression 
symptoms (7 questions). Subjects with a score of 22 marks 
or more were excluded. Based on the test results, 18 sam-
ples were excluded from the study (scores ≥ 22). In the 
cyclofem group, there were 123 participants, yet 3 were 
excluded (not meeting = 1 and lactation = 2). In the COC 
group, there were 133 participants, yet 13 were excluded 
(not meeting = 8 and using antidepressants by the female 
= 5), so 240 subjects were divided to 2 equal groups of 120 
each.
Cyclofem ampoule (manufactured by Iran Hormone Teh-
ran, Iran) contains 25 mg of medroxyprogesterone ace-
tate and 5 mg of estradiol cypionate, and was injected at 
monthly intervals, and COC (Aburaihan pharmaceutical 
Co, Tehran, Iran), containing 0.15 mg of levonorgestrel 
and 0.03 mg of ethinyle estradiol, was continuously ad-
ministered at 3-week intervals at health centers. The data 
collection tool was completed by the researchers through 
interviews. Next, questions about demographic variables 
with 33 questions were filled out. Finally, the Female Sexu-
al Function Index (FSFI) questionnaire that has been used 
in various studies, was completed [25, 26]. This question-
naire contained 19 questions with 6 options, with 2 ques-
tions on sexual desire, 4 on arousal, 4 on vaginal lubrica-
tion, 3 on orgasm, 3 on pain, and 3 on sexual satisfaction, 
designed with a Likert scale, and assesses sexual function 
over the past 4 weeks. Total score is obtained from the sum 
of 6 domain scores and ranges from 1.2 to 36. Maximum 
score was 36, and scores less than 28 indicated unfavor-
able sexual functions. In each area, the score range was 0 
to 6. Content validity was used to ascertain validity of the 
questionnaire, and internal consistency was ensured using 
Cronbach’s alpha coefficient (α = 0.81). For reliability, re-




analyzed with Statistical Package Software for Social Sci-
ence, version 16 (SPSS Inc., Chicago, IL, USA). Descrip-
tive statistics, independent t, Mann-Whitney test, and 
Chi-square, were used. An alpha level of less than 0.05 was 
accepted in all tests as statistically significant.
RESULTS
This study was conducted on 240 females, and their demo-
graphic details are presented in Table 1. All participants were 
Muslim. Sexual function in females using cyclofem was fa-
vorite (65.8%) compared to those using COC (73.3%). The 
FSFI scores for each group are shown in Table 2. The differ-
ence in total sexual function scores between cyclofem and 
COC groups was not significant (mean score of total sexual 
function in the COC group was 29.15 ± 6.13 versus 29.53 
± 4.23 in the cyclofem group), however, in terms of sexual 
desire and sexual arousal, the cyclofem group obtained low-
er scores than the COC group (mean score of desire domain 
in the COC group was 3.85 ± 1.31 versus 3.40 ± 0.78 in the 
cyclofem group; mean score of arousal domain in the COC 
group was 4.51 ± 1.39 versus 4.16 ± 0.86 in the cyclofem 
group. Comparison of sexual function in COC and Cyclofem 
users is indicated in Table 2 (P < 0.05).
Table 1: Distribution of the Demographic Characteristics of Females Consuming Combined Oral Contraceptives and Cyclofem
Variable COC (n = 120) Cyclofem (n = 120) Test P Value
Age, y(SD) 29.58(5.42) 28.26(5.08) Independent T NS
Age of marriage,y(SD) 19.92(3.98) 18.55(3.62) Independent T NS
Duration of marriage, y(SD) 9.57(5.94) 8.70(4.89) Independent T NS
Age of first conception, y(SD) 20.73(6.31) 21.12(4.84) Independent T NS
Gravidity(SD) 1.82(0.22) 2.15(1.22) Independent T NS
Duration of use, m(SD) 50.58(7.13) 50.32(7.83) Independent T NS
Menstruation status, No. (%)
Regular 107(89.2) 102(85)
Irregular 10(8.3) 17(14.2) Chi-square NS
Amenorrhea 3(2.5) 1(0.8)
Side effect, No. (%)




Primary school 18(15) 12(10)
Secondary school 20(16.7) 28(23.3) Chi-square NS
High school 67(55.8)  72(60)
Above 10(12) 6(5)
Table 2: Comparison of Sexual Function in Combined Oral Contraceptives Consumers and Cyclofem Users
Domain COC (n = 120) Cyclofem (n = 120) P Value
*Desire (3.80-5.6)4.21 (3.00-4.8)3.60 0.001a
*Arousal (4.1-5.8)5.10 (3.6-4.8)4.20 0.020a
*Lubrication (4.5-5.8)5.10 (4.5-6.0)5.25 0.116a
*Orgasm (4.2-6.0)5.10 (4.0-6.0)4.80 0.296a
*Pain (5.8-5.9)5.50 (5.2-6.0)6.00 0.246a
*Satisfaction (4.1-6.0)4.90 (3.6-6.0)4.80 0.812a
**Total (6.13)29.15 (4.23)29.53 0.102b








The effect of hormonal contraception on sexual function in 
users of contraceptives has been far less frequently studied. 
However, in the current study, the relationship between COC 
and Cyclofem and sexual function in females was insignificant. 
The authors did not find any study about this relationship yet 
the World Health Organization (WHO) (2007) and Lande 
and Richey (2006) reported no sufficient evidence that the 
use of combined injectable hormonal therapy changes female’s 
sexual function [27, 28]. In many studies, the role of hormon-
al contraceptives is controversial [25, 29-31]. The mechanism 
of action of COC is by suppression of ovulation; COC inhib-
its pituitary production and secretion of Follicle-Stimulating 
Hormone (FSH) and Luteinizing Hormone (LH), and blunts 
the mid-cycle surge of both hormones, which inhibits follicu-
lar development, ovulation, and corpus lutein formation. This 
process also blocks normal hypothalamic production of go-
nadotropin-releasing hormone. Cyclofem also prevents preg-
nancy by thickening the cervical mucus. The ovaries and adre-
nal glands produce about 50% of the circulating testosterone, 
whereas the other 50% comes from peripheral conversion of 
precursor steroids from the ovaries and adrenals. Most circu-
lating testosterone is bound to Sex Hormone-Binding Glob-
ulin (SHBG) and albumin, which leaves only 1% to 2%, as 
active free testosterone [32]. Estrogen-containing hormonal 
contraceptives increase levels of sex-hormone-binding globu-
lin, leading to a reduction in free testosterone levels; this effect 
is greater in formulations with higher estrogen content [33]. 
Strufaldi et al. (2010) argued the theory that low androgen 
levels in COC users contribute to a low libido, which was in-
vestigated by 2 studies. Females, who had taken androgen and 
higher free testosterone levels, showed significantly improved 
sexual function [33-35]. However, Shifren et al. (2000) found 
that androgen therapy is efficient in the treatment of females, 
who had Hypoactive Sexual Desire Disorder (HSDD) [36]. It 
is unknown whether this effect is linked to the conversion of 
androgens into estrogen or only to the direct effect of andro-
gen. The authors did not measure testosterone in their study. 
The females, who are more sensitive to testosterone changes, 
showed more sexual problems [37]. The role of sex hormones 
in protecting female’s sexual health is not clearly known. Hor-
monal effects may be influenced by many factors, including, 
biological such as adrenal hormone deficiency, effects of envi-
ronmental enzymes in cells, sensitivity of estrogen receptors, 
effects of the aromatase enzyme, number of sex steroid recep-
tors, and proteins [38]. Sexual problems related to hormonal 
contraception methods may be due to different physiological 
responses to hormone levels, so that the rate of sexual prob-
lems in some communities is less than in other communities 
[39]. However, the role of testosterone in female’s sexual 
arousal should be taken into consideration. The females, who 
are more sensitive to testosterone changes, experience more 
sexual problems [40]. In this study, cyclofem estrogen level 
is several times as ethinyl estradiol. Once the estradiol cypi-
onate enters circulation, it is hydrolyzed into estradiol, an 
endogenously occurring estrogen and inactive cyclopentane 
propionic acid. Estradiol cypionate is also an esterified form of 
natural 17β-estradiol. The natural estrogens are metabolized 
faster than synthetic ethinyl estradiol and have a lower bio-
availability [41, 42]. The binding of the estrogen to the body’s 
receptors occurs as estradiol rather than ethinyl estradiol [43]. 
Simber et al. (2007) concluded that a significant reduction in 
concentration of endometrial vessels occurs with cyclofem 
compared to before use and normal endometrium [44]. Es-
trogen levels have a complex effect on sexual function [45]. 
Changes in volume of vaginal wall and clitoris and local blood 
flow can also effect response to sexual stimuli [46]. Absence 
of estrogen cannot prevent vaginal lubrication, required for 
sexual stimuli [45]. Hormonal balance is essential in sexual 
function. Estradiol and nitric oxide play an important role in 
vaginal epithelium, and they also help vaginal lubrication. This 
is evident in cases of reduced estrogen level [46]. The role for 
estrogens is considerably more controversial [47]. The signif-
icant effect of estrogen on sexual interest and arousal is not 
supported by evidence [48]. In one study, the authors found 
a significant difference in sexual desire and arousal between 
COC and cyclofem users. The main reason for sexual activ-
ity was to preserve human generation. Sexual activity was 
initiated with sexual desire, which is generated by emotional 
and physical causes [49]. The sexual side effects of hormonal 
contraceptives are not well studied, particularly with regards 
to the impact on libido [32]. Many studies have investigated 
the relationship between estrogen dose and sexual desire [30, 
33, 50]. Pastor et al. (2013) observed that different doses of 
COCs have different effects. For COCs containing 20 to 35 μg 
EE, there was no change in sexual desire in most females [51]. 
Sexual arousal is highly complicated and can not be clearly dif-
ferentiated from desire [35]. Sexual desire may be influenced 
by biological, psychological, and cultural factors [25]. Bio-
logical factors do not act independently from environmental 
factors [52].
Sexual functioning is a complex process that depends on the 
neurological, vascular, and endocrine systems, and psychoso-
cial factors, such as self-concept and self-esteem [5]. Female’s 
sexual interest is influenced by their mental state, beliefs and 
values, expectations and sexual orientation, priorities and 
environmental conditions. Sexuality, desire, and arousal are 
severely affected by mental health and feelings of the sexual 
partner during the sexual intercourse [53]. Mental health is a 
predictor of sexual function. Females, who have good mental 
health have less distress about sex compared to other females. 
In fact, females with sexual problems received lower scores in 
the assessment of their mental health [54]. Self-confidence 
plays an important role in sexual issues. It is essential for es-
tablishing a balance, adaptation, and individual successes. 
Self-confidence is a pleasant internal energy for mental rela-
tions, which can cause neuropsychological balance and men-
tal health of the person. If this balance is not achieved, the 
person is exposed to stress [53]. Females with problems in 
sexual desire and arousal show anxiety, low self-confidence, 
and lack of emotional stability [54]. Love and emotional 
attachments can boost sexual desire [40]. Previous pleasur-
able experiences and favorable feelings toward their spouse 
can effect sexual satisfaction in females, which can prevent 
sexual dysfunction in cases of reduced sexual hormones [4]. 
Despite numerous studies, the role of sex hormones on sex-
ual function was doubtful and their predictions is not pos-
sible for all females, who use hormonal contraceptives. The 
authors recommend further studies in this area.
Study Limitations and Strengths




sexual dysfunction was not assessed. An effective factor in 
sexual function is spouse’s age and his health status. With 
aging of the spouse, erectile and ejaculatory dysfunction 
increases, and daily fatigue, work, and stress can effect sex-
ual function of males, and naturally that of females. Against 
this strength, the descriptive comparative design limited our 
causative assessment of sexual dysfunction in 2 types hor-
monal contraceptives. This study was conducted in Tehran 
province, so may not reflect the general population of Iran. 
In conclusion, although females have to use contraceptives to 
prevent unwanted pregnancies, they should choose the right 
contraceptive with the least effect on their sex life. Thus, we 
emphasize sexual counseling as part of family planning coun-
seling. When counseling a females on contraceptive options, 
it is important to present potential positive and negative im-
plications.
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